logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 12054533 B1

PDFFull Text
Date of Patent:
Aug. 06, 2024

Filed:

Jul. 06, 2022

Anti-vegf protein compositions and methods for producing the same

Applicant:

Regeneron Pharmaceuticals, Inc., Tarrytown, NY (US);

Inventors:

Andrew Tustian, Millwood, NY (US);

Ankit Vartak, Greenwich, CT (US);

Thomas Daly, New City, NY (US);

Erica Pyles, New City, NY (US);

Nisha Palackal, White Plains, NY (US);

Shunhai Wang, Scarsdlae, NY (US);

Ning Li, New Canaan, CT (US);

Assignee:

Regeneron Pharmaceuticals, Inc., Tarrytown, NY (US);

Attorney:

Kramer Levin Naftalis & Frankel LLP

Primary Examiner:

Jeffrey E Russel

Int. Cl.
CPC ...
C07K 1/36 (2006.01); A61K 38/18 (2006.01); C07K 1/113 (2006.01); C07K 1/16 (2006.01); C07K 1/18 (2006.01); C07K 1/22 (2006.01); C07K 14/71 (2006.01); C07K 16/22 (2006.01); C07K 16/28 (2006.01); C12N 5/00 (2006.01); C12N 15/66 (2006.01); C12P 21/02 (2006.01); C12P 21/06 (2006.01); G01N 30/80 (2006.01); G01N 30/02 (2006.01);
U.S. Cl.
CPC ...
C07K 14/71 (2013.01); A61K 38/1866 (2013.01); C07K 1/113 (2013.01); C07K 1/16 (2013.01); C07K 1/18 (2013.01); C07K 1/22 (2013.01); C07K 1/36 (2013.01); C07K 16/22 (2013.01); C07K 16/283 (2013.01); C12N 5/0018 (2013.01); C12N 5/0031 (2013.01); C12N 15/66 (2013.01); C12P 21/02 (2013.01); C12P 21/06 (2013.01); G01N 30/80 (2013.01); C07K 2317/622 (2013.01); C07K 2319/30 (2013.01); C07K 2319/33 (2013.01); C12N 2800/10 (2013.01); G01N 2030/027 (2013.01);
Abstract

The present disclosure pertains to methods for producing aflibercept from a host cell cultured in a chemically defined medium (CDM) including purification of aflibercept, wherein aflibercept following purification includes aflibercept variants that have at least one oxidized amino acid residue selected from the group consisting of tryptophan, histidine and a combination thereof.

Find Patent Forward Citations

Tustian, Andrew. (2024). Anti-vegf protein compositions and methods for producing the same (U.S. Patent No. 12054533). U.S. Patent and Trademark Office. https://idiyas.com/patent/badge/12054533

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Loading…